Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ibrutinib + venetoclax + obinutuzumab for Richter syndrome
MOH_2020-10-20_009351Phase 2Active, not recruiting
- Sponsor
- ד"ר תמר תדמור
- Start
- Oct 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib, venetoclax and obinutuzumab in Richter's syndrome (RS) and diffuse large B-cell lymphoma (DLBCL), sponsored by ד"ר תמר תדמור. Primary endpoint: Overall response rate. Started Oct 2020; status: active, not recruiting.
02
Drugs
ibrutinibvenetoclaxobinutuzumab
03
Conditions
Richter's syndrome (RS)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on MOH_2020-10-20_009351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-10-20_009351.